Cancer Research and Treatment

Original Article

Head and Neck cancer

Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Yi-Feng Yu, Peng Wu, Rui Zhuo, San-Gang Wu; Cancer Res Treat. 2024;56(4):1058-1067. Published online February 19, 2024; DOI: https://doi.org/10.4143/crt.2023.1343

Purpose
This study aimed to investigate the efficacy and safety of using metronomic S-1 adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC).
Materials and Methods
We retrospectively collected data on patients diagnosed with LANPC between January 2016 and December 2021. All patients were treated with induction chemotherapy and concurrent chemoradiotherapy with or without metronomic chemotherapy (MC). Toxicities during MC were recorded. The chi-square test, Kaplan-Meier methods, propensity score matching (PSM), and Cox proportional hazards model were used for statistical analyses.
Results
A total of 474 patients were identified, including 64 (13.5%) and 410 (83.5%) patients with or without receiving MC, respectively. Patients who received metronomic S-1 had significantly better 3-year locoregional recurrence-free survival (LRFS) (100% vs. 90.9%, p=0.038), distant metastasis-free survival (DMFS) (98.5% vs. 84.1%, p=0.002), disease-free survival (DFS) (98.4% vs. 77.5%, p < 0.001), and overall survival (OS) (98.0% vs. 87.7%, p=0.008) compared to those without metronomic S-1. The multivariate prognostic analysis revealed that metronomic S-1 was identified as an independent prognostic factor associated with better DMFS (hazard ratio [HR], 0.074; p=0.010), DFS (HR, 0.103; p=0.002) and OS (HR, 0.127; p=0.042), but not in LRFS (p=0.071). Similar results were found using PSM. Common adverse events observed in the metronomic S-1 group included leukopenia, neutropenia, increased total bilirubin, anorexia, rash/desquamation, and hyperpigmentation. All patients with adverse events were grade 1-2.
Conclusion
It is worth conducting a randomized controlled trial to assess the effect of metronomic S-1 on survival outcomes and toxicities of LANPC.

Citations

Citations to this article as recorded by

Risk Stratification in T4 or N3 Nasopharyngeal Carcinoma
Lin-Feng Guo, Lu-Chao Zhu, Yi-Feng Yu, Zhen-Zhen Lu, Qin Lin, San-Gang Wu
Cancer Research and Treatment.2026; 58(3): 728. CrossRef
Oral Metronomic Chemotherapy in Nasopharyngeal Carcinoma with Radiotherapy Interruptions: A Lesson Learned from the Lockdown Due to COVID-19
Yuan Zhou, Rui Zhou, Yi-Feng Yu, Zheng-Jie Huang, San-Gang Wu
Recent Patents on Anti-Cancer Drug Discovery.2026; 21(2): 201. CrossRef
Treatment and clinical outcomes among stage II–IVA nasopharyngeal carcinoma patients with undetectable pretreatment Epstein-Barr viral DNA
Ci-ming Sun, Zhen Xu, Cheng-hao Li, Jun-xiang Chen, Xin-yi Su, Jing-xia Song, Shuang-hong Song, Qing-qing Xu, Yan-Ling Wu
Frontiers in Medicine.2026;[Epub] CrossRef
Reply to Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”
San-Gang Wu
Cancer Research and Treatment.2025; 57(1): 291. CrossRef
Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”
Erkan Topkan, Efsun Somay, Nilufer Kılıc Durankus, Ugur Selek
Cancer Research and Treatment.2025; 57(1): 289. CrossRef
Two or three cycles of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma?
Lin-Feng Guo, Yi-Feng Yu, Zhen-Zhen Lu, Qin Lin, San-Gang Wu
BMC Cancer.2025;[Epub] CrossRef
Comment on “Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles”
Erkan Topkan, Efsun Somay, Duriye Ozturk, Ugur Selek
Clinical and Translational Radiation Oncology.2025; 54: 101025. CrossRef
Genetic algorithm-optimized neural network outperforms TNM staging in predicting rapidly progressive nasopharyngeal carcinoma: Reassessing adjuvant chemotherapy benefit via propensity score matching
Li-ting Ling, Wang-jian Li, Yue Yao, Kai-qing Tan, Bo-lin Zhu, Li-Qing Zhou, Song Qu, Ling Li, Ying Guan, Xiao-dong Zhu, Ling-hui Pan, Zhong-guo Liang
European Journal of Cancer.2025; 230: 115787. CrossRef
Metronomic chemotherapy in locoregionally advanced nasopharyngeal carcinoma with residual EBV-DNA after induction chemotherapy
Lin-Feng Guo, Liu-Yun Gong, Qin Lin, San-Gang Wu
Infectious Agents and Cancer.2025;[Epub] CrossRef
Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study
Shuhui Dong, Weixin Bei, Lanfeng Lin, Yaofei Jiang, Nian Lu, Guoying Liu, Yanqun Xiang, Weixiong Xia
Oral Oncology.2024; 156: 106908. CrossRef

6,605 View
151 Download
9 Web of Science
10 Crossref

First
Prev
Page of 1
Next
Last

Search